Valuation of Pharmaceuticals and Biotechnology - IP Marketing ...

thirdsafflowerBiotechnology

Dec 1, 2012 (4 years and 11 months ago)

198 views

Royalty Rates for Pharmaceuticals & Biotechnology – 7
th
Edition 6
TABLE OF CONTENTS
Very Unique Assets ____________________________________________________ 17
 
Business Enterprise Framework ___________________________________________ 18
 
Driving Forces Behind Royalty Rates ______________________________________ 23
 
Simplistic Rules of Thumb _______________________________________________ 24
 
Royalty Rates and Industry Guidelines _____________________________________ 27
 
Infringement Damages Analysis ___________________________________________ 29
 
Generic Pricing ________________________________________________________ 31
 
Comparable License Transactions _________________________________________ 33
 
Investment Rate of Return Analysis ________________________________________ 37
 
Discounted Cash Flow Analysis ___________________________________________ 43
 
Risk Adjusted Net Present Value __________________________________________ 49
 
Key Components of License Agreements ____________________________________ 57
 
Alcohol Dependency Treatment ___________________________________________ 61
 
Anesthetic ____________________________________________________________ 65
 
Animal Health Products _________________________________________________ 65
 
Antibodies - Primatized _________________________________________________ 66
 
Antibodies - Primatized _________________________________________________ 66
 
Antibodies - Primatized Anti-CD4 _________________________________________ 67
 
Anti-hypertension Therapy _______________________________________________ 68
 
Anti-infection Screening Process __________________________________________ 69
 
Anti-inflammatory Drug BB-882 __________________________________________ 70
 
Anti-inflammatory – Topical _____________________________________________ 71
 
Antifungal Agent – Amphotericin B________________________________________ 71
 
Antifungal ____________________________________________________________ 72
 
Anti-retroviral medicine - Viread __________________________________________ 72
 
Anti-viral Therapy _____________________________________________________ 74
 
Anti-viral and Anti-infective Therapies _____________________________________ 75
 
Antiviral and Anti-infective Therapies ______________________________________ 76
 
Arginine Products ______________________________________________________ 77
 
Rheumatoid Arthritis Drug Humira ________________________________________ 78
 
Asthma Drug – Oral Administration________________________________________ 78
 

Royalty Rates for Pharmaceuticals & Biotechnology – 7
th
Edition 7
Asthma Drug – Oral Administration________________________________________ 79
 
Attention Deficit Hyperactivity Disorder Therapy _____________________________ 80
 
Attention Deficit Hyperactivity Disorder ____________________________________ 80
 
Attention Deficit Hyperactivity Disorder ____________________________________ 81
 
Automated Cell Processing Instrument _____________________________________ 82
 
Automated Process Research _____________________________________________ 84
 
BetaKine (TGF-beta-2) __________________________________________________ 85
 
Bicifadine ____________________________________________________________ 86
 
Biochemical Technology Portfolio _________________________________________ 88
 
Blood Cell and Bone Marrow Production ___________________________________ 88
 
Blood Cell Therapy _____________________________________________________ 89
 
Blood Clot Formation Test _______________________________________________ 90
 
Blood Expander _______________________________________________________ 91
 
Blood Expander _______________________________________________________ 94
 
Blood Expander _______________________________________________________ 95
 
Blood – Hematology Controls Using Reticuulotytes ___________________________ 97
 
Blood Plasma Volume Expander __________________________________________ 98
 
BPI – Human Protein __________________________________________________ 101
 
Cancer Treatment – 9-Aminocamptothecin _________________________________ 101
 
Cancer - Aflibercept ___________________________________________________ 102
 
Cardiovascular – Adenocard Treatment ____________________________________ 103
 
Cardiovascular – Beta Blocker ___________________________________________ 104
 
Cardiovascular – Beta Blocker ___________________________________________ 105
 
Cardiovascular – Bextra™ ______________________________________________ 106
 
Cancer Treatment – Blood Cells __________________________________________ 107
 
Cancer Treatment – Carbohydrate Compounds ______________________________ 108
 
Cancer Treatment – Clofarabine __________________________________________ 109
 
Cancer – Ceeplen® Leukemia Treatment ___________________________________ 111
 
Cancer Treatment – DBD/Mitolactol ______________________________________ 112
 
Cancer Treatment – Disodium Clodronate __________________________________ 113
 
Cancer Treatment – Electrostatic Lipsome __________________________________ 114
 
Cancer Treatment – Foscan _____________________________________________ 116
 
I
NTELLECTUAL
P
ROPERTY
R
ESEARCH
A
SSOCIATES

8 Royalty Rates for Pharmaceuticals & Biotechnology – 7
th
Edition
Cancer Treatment – Gliadel _____________________________________________ 116
 
Cancer - Hedgehog Pathway Inhibitor _____________________________________ 117
 
Cancer- Histone Deacetylase (HDAC) Inhibitors ____________________________ 118
 
Cancer Treatment – huN901-DM1 Tumor-Activated Prodrug (TAP) _____________ 119
 
Cancer Treatment – Maytansinoid Tumor-Activated Prodrug (TAP) _____________ 120
 
Cancer Therapy – Myelodysplastic Syndrome _______________________________ 120
 
Cancer Therapy - NeoRx's Avicidin® _____________________________________ 121
 
Cancer Treatment – Oncolysin B _________________________________________ 122
 
Cancer Treatment OSI-774 ______________________________________________ 122
 
Cancer Treatment – Oxygen Enhancement _________________________________ 123
 
Cancer Treatment - Prostate _____________________________________________ 124
 
Cancer Treatment – Radio Labeled Antibody _______________________________ 125
 
Cancer Treatment - Ribonucleases ________________________________________ 125
 
Cancer – Small Cell ___________________________________________________ 126
 
Cancer - Tarceva ______________________________________________________ 128
 
Cancer Treatment - Vaccines ____________________________________________ 130
 
Cancer Therapy _______________________________________________________ 131
 
Cardiovascular – Angina Therapy ________________________________________ 131
 
Cardiovascular Generic Drug – ThromboClear ______________________________ 133
 
Cardiovascular Disease Theapy __________________________________________ 134
 
Cardiorenal Disease Therapies ___________________________________________ 135
 
Cartilage Regenerative Technology _______________________________________ 136
 
cdkl Assay ___________________________________________________________ 138
 
Coronary Drug-eluting Stent ____________________________________________ 139
 
Cell Adhesion Technology – LEC-CAM ___________________________________ 139
 
Cell Cultures _________________________________________________________ 140
 
Chimeric IgG1 antibodies _______________________________________________ 141
 
Chromosome Analysis Technology _______________________________________ 141
 
Chronic Obstructive Pulmonary Disease Therapy ____________________________ 143
 
Cochleates, Liposomes and Proteoliposomes ________________________________ 144
 
Cold Remedy ________________________________________________________ 148
 
Cold Remedy ________________________________________________________ 149
 

Royalty Rates for Pharmaceuticals & Biotechnology – 7
th
Edition 9
Collagenase Ointment __________________________________________________ 149
 
Consensus Interferon __________________________________________________ 150
 
Contraceptive ________________________________________________________ 151
 
Contrast Agent – Intravenous ____________________________________________ 152
 
Cough Medicine ______________________________________________________ 153
 
Cyclin Dependent Kinasc Assay Test Kit ___________________________________ 154
 
Cypress Stem Cells ____________________________________________________ 155
 
Cystic Fibrosis Treatment _______________________________________________ 155
 
Cytomegalovirus Intravenous Treatment ___________________________________ 156
 
Deferrum® deferiprone ________________________________________________ 157
 
Dermatology _________________________________________________________ 157
 
Dermatology _________________________________________________________ 158
 
Diabetes ____________________________________________________________ 158
 
Diabetes ____________________________________________________________ 159
 
Diabetes – PARL gene _________________________________________________ 159
 
Diabetes (Type II) Mellitus Drug _________________________________________ 160
 
Diagnostic Alliance ____________________________________________________ 160
 
Diagnostic Imagining Using Ligands ______________________________________ 161
 
Dietary Supplement – Botanical __________________________________________ 162
 
Diltiazem Heart Drug __________________________________________________ 163
 
DNA Binding Invention ________________________________________________ 163
 
DNA – PK ___________________________________________________________ 164
 
Drug Delivery ________________________________________________________ 165
 
Drug Delivery ________________________________________________________ 166
 
Drug Delivery ________________________________________________________ 167
 
Drug Delivery ________________________________________________________ 170
 
Drug Delivery – Controlled Release _______________________________________ 172
 
Drug Delivery System - Pulmonary _______________________________________ 173
 
Drug Development Technology __________________________________________ 174
 
Drug Development, Botanical-based ______________________________________ 175
 
EGF Fusion Protein ___________________________________________________ 176
 
Enoxaparin __________________________________________________________ 177
 
I
NTELLECTUAL
P
ROPERTY
R
ESEARCH
A
SSOCIATES

10 Royalty Rates for Pharmaceuticals & Biotechnology – 7
th
Edition
Environmental Test Kit _________________________________________________ 178
 
Enzyme Inhibitors _____________________________________________________ 180
 
Epilepsy Treatment – ADCI _____________________________________________ 180
 
EPO, Hepatitis B and IL-2 ______________________________________________ 181
 
Erythronmycin Antibiotic _______________________________________________ 182
 
Estrogen Replacement Therapy __________________________________________ 182
 
Fibrotic Disease Therapy - Pirfenidone ____________________________________ 183
 
Financing Research ____________________________________________________ 184
 
Financing Research ____________________________________________________ 185
 
Fusion Inihibitors for HIV ______________________________________________ 186
 
Gene Alteration Technology _____________________________________________ 187
 
Gene Activation Technology ____________________________________________ 187
 
Genetic Abnormalities Test– Prenatal _____________________________________ 188
 
Gene Splicing Technology ______________________________________________ 189
 
Genetically Engineered Listeria Immune Therapy ____________________________ 189
 
Genetic Research _____________________________________________________ 191
 
Gene Sequencing _____________________________________________________ 192
 
Gene Therapy Partnership Network _______________________________________ 192
 
Genetic Technology ___________________________________________________ 193
 
Genomics-based Drug Discovery _________________________________________ 194
 
Hepatitis B and C Genetic Therapy _______________________________________ 198
 
Hepatitis E Vaccine ___________________________________________________ 199
 
Hepatitis C protease Inhibitor ____________________________________________ 199
 
HIV Drugs ___________________________________________________________ 200
 
Hepatitis A Vaccine ___________________________________________________ 201
 
Hepatitis B & C Treatment ______________________________________________ 201
 
Hepatitis C- Telaprevir _________________________________________________ 202
 
HIV and AIDS – Protease Inhibitor Therapy ________________________________ 204
 
HIV Treatment – alpha interferon ________________________________________ 204
 
HIV Treatment – interferon-g ____________________________________________ 204
 
HIV Treatment – (NNRTI) ______________________________________________ 205
 
HIV Diagnosis and Treatment ___________________________________________ 205
 

Royalty Rates for Pharmaceuticals & Biotechnology – 7
th
Edition 11
HIV and Hepatitis Vaccines _____________________________________________ 206
 
HIV Vaccine _________________________________________________________ 207
 
Human Gene Technology _______________________________________________ 208
 
Human Growth Hormone _______________________________________________ 214
 
Human Monoclonal Antibodies Discovery Technology _______________________ 215
 
Humanized Antibody __________________________________________________ 217
 
Humanized Monoclonal Antibody ________________________________________ 218
 
Humanization Antibody ________________________________________________ 219
 
Hypertension Treatment- autologous gene therapy ___________________________ 219
 
Hypertension Treatment- tadalafil ________________________________________ 220
 
Immune System Regulators – Cytokines ___________________________________ 222
 
Immunodeficiency ____________________________________________________ 223
 
Immunotoxin – MDX-RA _______________________________________________ 224
 
Indiplon _____________________________________________________________ 225
 
Inflammatory – Topical Therapy _________________________________________ 225
 
Inflammation Antibody-based Therapeutics ________________________________ 226
 
Influenza Drug _______________________________________________________ 226
 
Insomnia Therapy _____________________________________________________ 227
 
Insomnia ____________________________________________________________ 227
 
Intracellular Receptor Technology ________________________________________ 229
 
Integrelin Drug _______________________________________________________ 230
 
Interferon Gamma-1b __________________________________________________ 231
 
Kidney Disease Treatment ______________________________________________ 234
 
Kidney Failure Treatment _______________________________________________ 235
 
Living Cells Connective Tissue __________________________________________ 236
 
Lubrin® _____________________________________________________________ 236
 
Mammary Cell Growth Inhibitor _________________________________________ 237
 
Michellamine B/Tropical Vine Leaves _____________________________________ 238
 
Microorganism Detection in Water _______________________________________ 238
 
Microsponge Delivery System ___________________________________________ 239
 
Migraine Relief _______________________________________________________ 239
 
Modulation of Opioid Receptors _________________________________________ 240
 
I
NTELLECTUAL
P
ROPERTY
R
ESEARCH
A
SSOCIATES

12 Royalty Rates for Pharmaceuticals & Biotechnology – 7
th
Edition
Monoclonal Antibodies Binding to TGF-B _________________________________ 240
 
Monoclonal Antibody Technology ________________________________________ 242
 
Monoclonal Antibody Technology ________________________________________ 243
 
Monoclonal Antibody 45-J Test __________________________________________ 244
 
Monoclonal Antibodies to Gram Negative Sepsis-Related Bacteria ______________ 244
 
Multiple Sclerosis Therapy - Copaxone ____________________________________ 246
 
Naked DNA Technology _______________________________________________ 247
 
Nanocrystalline Particles _______________________________________________ 249
 
NASA Technology ____________________________________________________ 250
 
Nasal Vitamin B-12 Therapy ____________________________________________ 251
 
Natural Cell Signaling Phenomenon _______________________________________ 252
 
Nerve Repair _________________________________________________________ 252
 
Nervous System Therapeutics ___________________________________________ 253
 
Neurodegenerative and Psychiatric Diseases Therapy _________________________ 254
 
Neurological Therapeutics ______________________________________________ 256
 
Neurological Peptide Therapy ___________________________________________ 257
 
Nicotine Addiction Treatment ___________________________________________ 259
 
Nifedipine Crystals ____________________________________________________ 261
 
Novasome Lipid Vesicles Encapsulation Technology _________________________ 261
 
Nuclear Matrix Protein Technology _______________________________________ 262
 
Nucleic Acid Sequences for Detection _____________________________________ 262
 
Nucleic Acid Probe Technology __________________________________________ 263
 
Nucleic Acid Targeting _________________________________________________ 263
 
Nucleic Acid Technologies ______________________________________________ 263
 
NeuroCell Joint Venture ________________________________________________ 265
 
Neurological Disorders _________________________________________________ 265
 
Nureologogical Disorders Anti-agitation Drug ______________________________ 266
 
Nureologogical Disorders Anti-agitation Drug ______________________________ 267
 
Neurotrophic Factor Commercialization ___________________________________ 268
 
Nutrition – Salt Alternative ______________________________________________ 269
 
Obesity Therapy ______________________________________________________ 270
 
Opthalmic – Patent Formulation for Loteprednol Etabonate ____________________ 270
 

Royalty Rates for Pharmaceuticals & Biotechnology – 7
th
Edition 13
Oral Contraceptive ____________________________________________________ 271
 
Osteoporosis Compound 1-apiha-hydroxyvitamin D2 _________________________ 272
 
Oxygenation _________________________________________________________ 272
 
Pain Management _____________________________________________________ 273
 
Pain Management _____________________________________________________ 273
 
Pain Management _____________________________________________________ 274
 
Pain Management _____________________________________________________ 275
 
Pain Management _____________________________________________________ 276
 
Pain Management _____________________________________________________ 276
 
Pain Management _____________________________________________________ 277
 
Pain Management _____________________________________________________ 277
 
Pain Management _____________________________________________________ 278
 
Pain Management _____________________________________________________ 278
 
Pain Management _____________________________________________________ 279
 
Pain Management _____________________________________________________ 279
 
Pain Management _____________________________________________________ 280
 
Pain Management _____________________________________________________ 280
 
Pain Management _____________________________________________________ 281
 
Pain Management _____________________________________________________ 281
 
Pain Management _____________________________________________________ 282
 
Pain Management _____________________________________________________ 282
 
Pain Management _____________________________________________________ 282
 
PEG Enhanced L-asparaginase ___________________________________________ 283
 
Pegylated Reagent _____________________________________________________ 286
 
Personal Care – Bioadhesive Delivery System _______________________________ 288
 
Personal Care – Cosmetic Liposomal Formulations ___________________________ 288
 
Personal Care – Facial Hair Treatment _____________________________________ 288
 
Personal Care – Hand Cleanser __________________________________________ 289
 
Personal Care - Kinetin™ Skin-Care Treatment _____________________________ 289
 
Personal Care – Melanin Sunscreen Agent __________________________________ 290
 
Personal Care – Moisturizers ____________________________________________ 291
 
Personal Care – Moisturizers ____________________________________________ 291
 
I
NTELLECTUAL
P
ROPERTY
R
ESEARCH
A
SSOCIATES

14 Royalty Rates for Pharmaceuticals & Biotechnology – 7
th
Edition
Personal Care – Mycrobicide Lotion ______________________________________ 291
 
Personal Care – Oral Treatment __________________________________________ 292
 
Personal Care – Serine Elastase Inhibitor Compound _________________________ 292
 
Personal Care – Skin Barrier Repair _______________________________________ 292
 
Personal Care – Skin Care Moisturizers ____________________________________ 293
 
Personal Care – Topical Antiseptics _______________________________________ 293
 
Personal Care – Various Products ________________________________________ 293
 
Platinate HPMA Copolymer _____________________________________________ 294
 
Photodynamic Therapy _________________________________________________ 294
 
Polymerase Chain Reaction Technology ___________________________________ 296
 
Polymerase Chain Reaction Technology ___________________________________ 298
 
Polymerase Chain Reaction Technology ___________________________________ 298
 
Poly (ADP Ribose) Polymerase Diagnostic Assay ____________________________ 299
 
Pre-eclampsia/Toxemia Diagnosis and Therapy _____________________________ 300
 
Pro-Apolipoprotein A-I and Lipid Complexes _______________________________ 301
 
Progesterone Gel ______________________________________________________ 301
 
Protein Secretion Technology ____________________________________________ 303
 
Proteomics Technology ________________________________________________ 303
 
Psychiatric And Psychotic Therapy _______________________________________ 304
 
Psychotherapeutic Drugs _______________________________________________ 305
 
Pulmonary Disease ____________________________________________________ 305
 
Radynilel Hypoxic Tumor Cell Radiosensitizer ______________________________ 307
 
Rapid Diagnostic Test __________________________________________________ 308
 
RAS Human Protein/Rational Drug Design _________________________________ 309
 
Recombinant Technology _______________________________________________ 310
 
Recombinant Human Erythropoietin- Procrit® ______________________________ 310
 
Recombinant Human Inerlukin-twelve (rhIL-1 2) ____________________________ 311
 
Respiratory Therapy ___________________________________________________ 312
 
Retinoids ____________________________________________________________ 313
 
Rhenium Radiotherapy and Monoclonal Antibodies __________________________ 315
 
Ribozymes ___________________________________________________________ 316
 
RNAi Interference Technology __________________________________________ 316
 

Royalty Rates for Pharmaceuticals & Biotechnology – 7
th
Edition 15
RNAi Interference Technology __________________________________________ 319
 
RNAi Interference Therapies ____________________________________________ 322
 
Sarafem® ___________________________________________________________ 323
 
Schizophrenia ________________________________________________________ 323
 
Schizophrenia and Bipolar Treatment _____________________________________ 324
 
Septic Shock Treatment - Human Thymosin beta 4 (Tβ4), a 43-amino acid peptide _ 326
 
Sexual Dysfunction Therapy ____________________________________________ 328
 
Sleep Therapy – Nasal Administration _____________________________________ 329
 
Skin Technology - Polyactive Polymer Biomaterial __________________________ 331
 
Spirulina ____________________________________________________________ 331
 
Spleen Tyrosine Kinase (Syk) Inhibitor ____________________________________ 332
 
Stem Cells ___________________________________________________________ 332
 
Stem Cell Proliferation Factor ___________________________________________ 334
 
Stem Cell Technology and Materials ______________________________________ 335
 
Stem Cells – Pluripotent Novel Strains ____________________________________ 336
 
Stem-loop Vector Technology ___________________________________________ 338
 
Stromal Derived Factor 1 (SDF-1) Peptide Agonists and Antagonists ____________ 339
 
Tamiflu™ ___________________________________________________________ 339
 
Telavancin™ – Antibotic _______________________________________________ 340
 
Thalidomide _________________________________________________________ 340
 
Thalidomide Analogs __________________________________________________ 341
 
Tissue Malignancy Treatments ___________________________________________ 343
 
Thymidine Kinase Isoenzyme Diagnostics __________________________________ 344
 
TGF-beta ____________________________________________________________ 344
 
Transdermal Estrogen Patch _____________________________________________ 346
 
Tropical Plants _______________________________________________________ 347
 
Ultrasound Contrast Agent ______________________________________________ 347
 
Vaccines, gene-based __________________________________________________ 348
 
Vaccine Research _____________________________________________________ 350
 
Virus Vaccines _______________________________________________________ 351
 
Wart Removal Products ________________________________________________ 352
 
Water-Jel Sterile Burn Dressings _________________________________________ 353
 
I
NTELLECTUAL
P
ROPERTY
R
ESEARCH
A
SSOCIATES

16 Royalty Rates for Pharmaceuticals & Biotechnology – 7
th
Edition
Eli Lilly & Co. Experiences Compulsory License Royalty Rates ________________ 354
 
Company Index _______________________________________________________ 356